Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks
STANFORD HEALTH CARE, UCSF, & ORACLE
The Microbiome - A Modifiable Biomarker?
In perpetual awe of how 'simple' microbial organisms can perturb complex, multicellular eukaryotic organisms, our research program seeks to inspect, characterize and dissect the microbe-human interface. Infectious and environmental exposures result in drastic and sometimes fatal health consequences. In this session Dr. Bhatt will describe how her group uses modern genetic, molecular and computational techniques to better understand host-microbe interactions and decipher how perturbation of these interactions may result in human disease.
Harnessing Deep Sequencing Technologies for Surveillance of the Virome
The virome is a key and often under-appreciated part of the microbiome. In-depth investigations of the virome by metagenomic deep sequencing of clinical samples has a number of applications including pathogen discovery, clinical diagnosis, and molecular epidemiology. Viral infections in early life are thought to play a critical role in growth and development. In this session Dr. Chiu will discuss the development of tools and technologies to interrogate the virome and its associations with both health and disease.
Exploring the Microbiome for Novel Therapeutics
The human microbiome is increasingly understood to play a key role in human health and wellness, and changes to the microbiome have been linked to a wide range of diseases. Leveraging the microbiome for novel therapies requires a move past correlative relationships between the microbiome and disease, and instead a focus on the mechanistic interactions between the microbiome and host. These insights then enable the discovery and development of microbiome-derived therapeutics for chronic diseases.
Ami S. Bhatt, M.D., Ph.D., Assistant Professor of Medicine and Genetics, Stanford University
Dr. Bhatt is an Assistant Professor of Medicine and Genetics at Stanford University. A 2014 ASH Scholar and 2014 Amy Strelzer Manasevit Award Winner, she seeks to improve outcomes in patients with hematological malignancies by exhaustively characterizing the dynamics of the microbiome in immunocompromised individuals. Read Full Bio
Charles Chiu, M.D., PH.D, Asst. Prof., UCSF Lab. Med. & Infec. Diseases, Director, UCSF-Abbott Viral Dx & Discovery Center
Dr. Chiu is an expert in the development and implementation of advanced genomic technologies for pathogen discovery and clinical diagnostics, including microarrays and next-generation sequencing, for a variety of blood-borne infections. His efforts in Lyme disease focus on the development of diagnostics for both pathogen detection and host response. Read Full Bio
Peter DiLaura, President and CEO, Second Genome
Prior to Second Genome, Peter was the Senior Vice President of Products and Marketing at Ingenuity Systems, where he was responsible for a variety of roles on the senior management team including business development, global sales and marketing, and corporate strategy. Prior to Ingenuity, Peter held roles at Chemdex/Ventro and IBM. Read Full Bio
David Cook, Ph.D., EVP of Research & Development & CSO, Seres Therapeutics
David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. ("Seres"). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Read Full Bio